XML 43 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisitions and Strategic Transaction Expenses Business Combination (Tables)
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2015
Business Acquisition [Line Items]    
Business Acquisition, Pro Forma Information [Table Text Block]
(In millions)
 
Revenue
 
Earnings
Actual from 2/3/2017 - 12/31/2017(3)
 
$
1,062

 
*
2017 supplemental pro forma from 1/1/2017 - 12/31/2017(1)(2)
 
$
1,293

 
$
180

2016 supplemental pro forma from 1/1/2016 - 12/31/2016(1)(2)
 
$
1,418

 
$
22

______________________________
* Impracticable to calculate.
(1) 2017 supplemental pro forma earnings were adjusted to exclude $66.3 million of nonrecurring expense related to the fair value adjustment to acquisition-date inventory and $69.5 million of acquisition and integration-related costs. 2016 supplemental pro forma earnings were adjusted to include these charges.
  
Excelsior [Member]    
Business Acquisition [Line Items]    
Schedule of Business Acquisitions, by Acquisition [Table Text Block]  
The following table summarizes the final purchase price and the allocation of the purchase price related to the assets and liabilities retained (in thousands):

Fair Value of Consideration:
 
   Cash, net of cash acquired
$
56,786

 
 
Allocation of the Purchase Price:
 
   Net assets sold to Excelsior Medical, LLC
$
28,970

   Prepaid expenses and other current assets
254

   Deferred tax asset/liabilities
4,426

   Property, plant and equipment
3,982

   Identifiable intangible assets(1)
18,076

   Goodwill
4,985

   Assumed liabilities
(3,907
)
      Net Assets Acquired
$
56,786

______________________________
(1) Identifiable intangible assets included $7.1 million of non-contractual customer relationships, $3.7 million of developed technology and $7.3 million of trade name. The weighted-average amortization period for the total identifiable intangible assets is approximately fourteen years. The weighted-average amortization period for customer relationships and trade name is fifteen years and the weighted-average amortization period for the developed technology is ten years.
Hospira [Member]    
Business Acquisition [Line Items]    
Schedule of Business Acquisitions, by Acquisition [Table Text Block]
The following table summarizes the final purchase price and the final allocation of the purchase price related to the assets and liabilities purchased (in thousands, except per share data):

Cash consideration for acquired assets
 
$
180,785

Fair value of Seller Note
 
75,000

Fair value of contingent consideration payable to Pfizer (long-term)
 
19,000

 
 
 
Issuance of ICU Medical, Inc. common shares:
 
 
Number of shares issued to Pfizer
 
3,200

Price per share (ICU's trading closing share price on the Closing Date)
 
$
140.75

Market price of ICU shares issued to Pfizer
 
$
450,400

Less: Discount due to lack of marketability of 8.3%
 
(37,261
)
Equity portion of purchase price
 
413,139

Total Consideration
 
$
687,924

 
 
 
Purchase Price Allocation:
 
 
Cash and cash equivalents
 
$
31,082

Trade receivables
 
362

Inventories
 
417,622

Prepaid expenses and other assets
 
13,911

Property, plant and equipment
 
288,134

Intangible assets(1)
 
131,000

Other assets
 
29,270

Accounts payable
 
(12,381
)
Accrued liabilities
 
(47,936
)
Long-term liabilities(2)
 
(67,170
)
Total identifiable net assets acquired
 
$
783,894

Deferred tax, net
 
(25,080
)
Estimated Gain on Bargain Purchase
 
(70,890
)
Estimated Purchase Consideration
 
$
687,924

______________________________

(1) Identifiable intangible assets includes $48 million of customer relationships, $44 million of developed technology - pumps and dedicated sets, $34 million of developed technology - consumables, and $5 million of in-process research and development ("IPR&D"). The weighted amortization period for the total identifiable assets is approximately nine years, for customer relationships the weighted amortization period is eight years, for the developed technology - pumps and dedicated sets the weighted amortization period is ten years and for the developed technology - consumables the weighted amortization period is twelve years. The IPR&D is non-amortizing until the associated research and development efforts are complete.

(2) Long-term liabilities primarily consisted of contract liabilities, product liabilities and long-term employee benefits.